Methods comprising apoptosis inhibitors for the generation of transgenic pigs |
 |
|
|
||||||||||||||||||||||||||||||||||||||||||
| Title: | Human gene/protein involved in chronic myelogenous leukemia |
| Inventors: | Carpino, Nicholas A.; Memphis, TN, USA Kobayashi, Ryuji; Syosset, NY, USA Wisniewski, David G.; Staten Island, NY, USA Strife, Annabel O'C.; New York, NY, USA Clarkson, Bayard D.; New York, NY, USA |
| Summary: | This invention introduces a novel isolated human p62dok protein, methods and uses thereof. Central to the invention is the chimeric p120bcr-abl protein characteristic of chronic myelogenous leukemia (CML), which possesses elevated protein tyrosine kinase activity relative to normal c-abl tyrosine kinase. Described herein are techniques by which hematopoietic progenitor cells that have been isolated from CML patients in the chronic phase are shown to contain a constitutively tyrosine phosphorylated protein that migrates at approximately 62 kDa by SDS-PAGE and associates with the p120 ras GTPase-activating protein (GAP). This novel protein is identified herein as p62dok (p62 protein downstream of tyrosine kinases), and methods are disclosed for its isolation from a hematopoietic cell line expressing p120bcr-abl. Further provided are methods by which p62dok associated with GAP correlates with its tyrosine phosphorylation. Claims of the invention include activation of p62dok by the c-kit receptor which results in rapid tyrosine phosphorylation, implicating it as a component of a signal transduction pathway downstream of receptor tyrosine kinases. Therapeutic applications to the treatment of chronic myelogenous leukemia are included. |
| Abstract: | |
| US Patent Website: | Click Here for Full Text of Patent |
| Title Number: | US6100386 |
| Application Number: | US1997000787091 |
| Date Filed: | 22/01/1997 |
| Date Published: | 08/08/2000 |
| Assignee: | Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA Sloan-Kettering Institute for Cancer Research, New York, NY, USA |